Management of cardiovascular disease in patients with psoriasis

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 11, 2016, Pages 1509-1516

  Egeberg, Alexander ^a   Skov, Lone ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Cardiovascular disease; inflammation; psoriasis; therapy

Indexed keywords

ANTIINFLAMMATORY AGENT; CHOLESTEROL;

ALCOHOL CONSUMPTION; ANTIINFLAMMATORY ACTIVITY; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE SEVERITY; EXERCISE; FRAMINGHAM RISK SCORE; HUMAN; INFLAMMATION; LIFESTYLE MODIFICATION; MASS SCREENING; PRACTICE GUIDELINE; PSORIASIS; REVIEW; SMOKING CESSATION; ADVERSE EFFECTS; ALCOHOLISM; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; DRINKING BEHAVIOR; RISK FACTOR; RISK REDUCTION;

ALCOHOL DRINKING; ALCOHOLISM; CARDIOVASCULAR DISEASES; DISEASE MANAGEMENT; HUMANS; PSORIASIS; RISK FACTORS; RISK REDUCTION BEHAVIOR;

EID: 84978782614     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1080/14656566.2016.1190336     Document Type: Review

References (108)

1. R.Parisi, D.P.M.Symmons, C.E.M.Griffiths, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
2. C.J.McDonald, P.Calabresi Occlusive vascular disease in psoriatic patients. N Engl J Med. 1973;288(17):912.
3. C.J.McDonald, P.Calabresi. Thromboembolic disorders associated with psoriasis. Arch Dermatol. 1973;107(6):918.
4. L.Mallbris, O.Akre, F.Granath, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225–230.•• First comprehensive report on cardiovascular mortality in psoriasis.
5. L.Mallbris, F.Granath, A.Hamsten, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–621.• Demonstrated lipid abnormalities at onset of psoriasis, suggesting a genetic predisposition.
6. J.M.Gelfand, A.L.Neimann, D.B.Shin, et al. Risk of myocardial infarction in patients with psoriasis. Jama. 2006;296(14):1735–1741.•• First study to suggest an increased risk for myocardial infarction, especially in young patients with severe psoriasis.
7. J.M.Gelfand, A.B.Troxel, J.D.Lewis, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493–1499.
8. A.Ogdie, A.B.Troxel, N.N.Mehta, et al. Psoriasis and cardiovascular risk: strength in numbers part 3. J Invest Dermatol. 2015;135(9):2148–2150.
9. A.B.Alexandroff, M.Pauriah, R.D.Camp, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161(1):1–7.
10. P.Libby, P.M.Ridker, G.K.Hansson, et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–2138.
11. G.K.Hansson. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
12. O.Ahlehoff, L.Skov, G.Gislason, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–1134.
13. K.Abuabara, H.Lee, A.B.Kimball. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165(5):1066–1073.
14. A.W.Armstrong, E.A.Brezinski, M.R.Follansbee, et al. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20(4):500–512.
15. Y.J.Chen, Y.T.Chang, J.L.Shen, et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum. 2012;64(6):1879–1887.
16. N.N.Mehta, Y.Yu, R.Pinnelas, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775e1–775e6.
17. N.N.Mehta, P.Krishnamoorthy, Y.Yu, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–798.
18. P.Gisondi, S.Farina, M.V.Giordano, et al. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol. 2010;106(12):1754–1757.
19. M.Gyldenlove, P.Jensen, A.Linneberg, et al. Psoriasis and the Framingham risk score in a Danish hospital cohort. Int J Dermatol. 2014;53(9):1086–1090.
20. Task Force for the management of dyslipidaemias of the European Society of Cardiology, the European Atherosclerosis Society, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(Suppl 1):S1–S44.
21. M.J.Peters, D.P.Symmons, D.McCarey, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.
22. W.H.Boehncke, S.Boehncke. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14(4):343–348.
23. E.J.Samarasekera, J.M.Neilson, R.B.Warren, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346.
24. O.Ahlehoff, G.H.Gislason, M.Charlot, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–157.
25. A.Ogdie, Y.Yu, K.Haynes, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–332.
26. E.Salahadeen, C.Torp-Pedersen, G.Gislason, et al. Nationwide population-based study of cause-specific death rates in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29(5):1002–1005.
27. W.P.Gulliver, D.Macdonald, N.Gladney, et al. Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. J Cutan Med Surg. 2011;15(1):37–47.
28. M.Gaeta, S.Castelvecchio, C.Ricci, et al. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. Int J Cardiol. 2013;168(3):2282–2288.
29. O.Ahlehoff, G.H.Gislason, C.H.Jorgensen, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J. 2012;33(16):2054–2064.
30. O.Ahlehoff, G.H.Gislason, J.Lindhardsen, et al. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med. 2011;270(3):237–244.
31. O.Ahlehoff, G.H.Gislason, J.Lindhardsen, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2011;6(3):e18125.
32. U.Khalid, O.Ahlehoff, G.H.Gislason, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743–748.
33. R.Parisi, M.K.Rutter, M.Lunt, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol. 2015;135(9):2189–2197.• Used same registries as Ref. [6], but found no increased risk of major adverse cardiovascular events, except in subanalyses where psoriatic arthritis was excluded.
34. E.A.Dowlatshahi, E.A.van der Voort, L.R.Arends, et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169(2):266–282.
35. J.C.Mason, P.Libby. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482–489c.
36. Y.Wang, H.Gao, C.M.Loyd, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012;132(8):2067–2075.
37. W.H.Boehncke, S.Boehncke, A.M.Tobin, et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307.
38. D.D.Balci, A.Balci, S.Karazincir, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):1–6.
39. M.Gyldenlove, H.Storgaard, J.J.Holst, et al. Patients with psoriasis are insulin resistant. J Am Acad Dermatol. 2015;72(4):599–605.
40. J.Dave, M.A.Ahlman, B.N.Lockshin, et al. Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique. J Am Acad Dermatol. 2014;70(6):1137–1138.
41. N.N.Mehta, Y.Yu, B.Saboury, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–1039.• The first description of in vivo whole body inflammation in psoriasis detected by FDG-PET/CT in viscera, vasculature, and musculoskeletal structures.
42. N.N.Mehta, D.A.Torigian, J.M.Gelfand, et al. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;63:e3777.
43. K.F.Hjuler, M.Bottcher, C.Vestergaard, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. Am J Med. 2015;128(12):1325–34e2.
44. N.N.Mehta, R.Li, P.Krishnamoorthy, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218–221.
45. P.M.Ridker. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT). J Thromb Haemost. 2009;7(Suppl 1):332–339.
46. A.W.Armstrong, C.T.Harskamp, E.J.Armstrong. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.
47. N.Al-Mutairi, T.Nour. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14(6):749–756.
48. A.W.Armstrong, C.T.Harskamp, E.J.Armstrong. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatology. 2013;149(1):84–91.
49. A.W.Armstrong, C.T.Harskamp, E.J.Armstrong. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–442; discussion 42-3.
50. U.Khalid, P.R.Hansen, G.H.Gislason, et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013;36(8):2402–2407.
51. T.Torres, N.Bettencourt, D.Mendonca, et al. Epicardial adipose tissue and coronary artery calcification in psoriasis patients. J Eur Acad Dermatol Venereol. 2015;29(2):270–277.
52. A.W.Armstrong, C.T.Harskamp, J.S.Dhillon, et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304–314.
53. A.Egeberg, L.E.Bruun, L.Mallbris, et al. Family history predicts major adverse cardiovascular events in young adults with psoriasis. J Am Acad Dermatol. 2016. [In press]
54. E.Choy, N.Sattar. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460–469.
55. M.Holzer, P.Wolf, M.Inzinger, et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol. 2014;134(3):635–642.
56. C.Roubille, V.Richer, T.Starnino, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489.
57. S.Prodanovich, F.Ma, J.R.Taylor, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–267.• Study suggesting that reduction of inflammation may confer cardiovascular protection in patients with psoriasis.
58. C.Ryan, C.L.Leonardi, J.G.Krueger, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Jama. 2011;306(8):864–871.
59. J.A.Martin, S.Laube, C.Edwards, et al. Rate of acute adverse events for narrow-band UVB and Psoralen-UVA phototherapy. Photodermatol Photoimmunol Photomed. 2007;23(2–3):68–72.
60. N.Robert, G.W.Wong, J.M.Wright. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;1:CD007893.
61. M.J.Stiller, G.H.Pak, C.Kenny, et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol. 1992;27(3):434–438.
62. M.C.Gulliford, J.Charlton, R.Latinovic. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728–2729.
63. M.W.van der Linden, F.J.Penning-van Beest, T.Nijsten, et al. Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands. Drug Saf. 2009;32(6):527–537.
64. Z.Zhang, P.Zhao, A.Li, et al. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm. 2009;2009:389720.
65. B.M.Everett, A.D.Pradhan, D.H.Solomon, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(2):199–207e15.
66. D.H.Solomon, E.Massarotti, R.Garg, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. Jama. 2011;305(24):2525–2531.
67. E.A.Brezinski, M.R.Follansbee, E.J.Armstrong, et al. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20(4):513–528.
68. T.Pina, A.Corrales, R.Lopez-Mejias, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol. 2016 [Epub ahead of print].
69. J.J.Wu, K.Y.Poon, J.C.Channual, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250.
70. J.A.Singh, G.A.Wells, R.Christensen, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
71. A.D.Hauer, C.Uyttenhove, P.De Vos, et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112(7):1054–1062.
72. C.Rios-Navarro, C.de Pablo, V.Collado-Diaz, et al. Differential effects of anti-TNF-alpha and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions. Eur J Pharmacol. 2015;765:355–365.
73. C.Paul, J.Cather, M.Gooderham, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
74. K.A.Papp, M.A.Menter, M.Abe, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961.
75. T.Torres, I.Raposo, M.Selores. IL-17 blockade in psoriasis: friend or foe in cardiovascular risk? Am J Clin Dermatol. 2016;17(2):107–112.
76. O.J.de Boer, J.J.van der Meer, P.Teeling, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499–508.
77. C.Erbel, M.Akhavanpoor, D.Okuyucu, et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol. 2014;193(9):4344–4355.
78. A.Gistera, A.K.Robertson, J.Andersson, et al. Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 2013;5(196):196ra00.
79. S.Taleb, M.Romain, B.Ramkhelawon, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206(10):2067–2077.
80. T.Simon, S.Taleb, N.Danchin, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577.
81. J.Y.Ryoo, H.J.Yang, E.Ji, et al. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann Pharmacother. 2016;50(5):341–351.
82. K.B.Gordon, C.L.Leonardi, M.Lebwohl, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176–1182.
83. Y.B.Brauchli, S.S.Jick, C.R.Meier. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol. 2011;65(1):77–83.
84. P.Wolkenstein, J.Revuz, J.C.Roujeau, et al. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology. 2009;218(2):103–109.
85. G.Chodick, D.Weitzman, V.Shalev, et al. Adherence with statins and the risk of psoriasis: a population-based cohort study. Br J Dermatol. 2015;173(2):480–487.
86. M.Naseri, A.Hadipour, M.Sepaskhah, et al. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger Med J Nat Assoc Res Doctors Niger. 2010;19(1):58–61.
87. A.Hilgendorff, H.Muth, B.Parviz, et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41(9):397–401.
88. I.I.Ivanov, B.S.McKenzie, L.Zhou, et al. The orphan nuclear receptor RORgamma T directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133.
89. S.Fujita-Sato, S.Ito, T.Isobe, et al. Structural basis of digoxin that antagonizes RORgamma T receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J Biol Chem. 2011;286(36):31409–31417.
90. J.Lee, S.Baek, J.Lee, et al. Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. Int Immunopharmacol. 2015;26(1):103–111.
91. O.Ahlehoff, L.Skov, G.Gislason, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One. 2012;7(4):e36342.
92. A.B.Kimball, P.Szapary, U.Mrowietz, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67(1):76–85.
93. P.Gisondi, M.Del Giglio, V.Di Francesco, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242–1247.
94. P.Jensen, C.Zachariae, R.Christensen, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatology. 2013;149(7):795–801.
95. P.Jensen, C.Zachariae, R.Christensen, et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. Acta Derm Venereol. 2014;94(6):691–694.
96. Y.K.Do, N.Lakhani, R.Malhotra, et al. Association between psoriasis and leisure-time physical activity: findings from the national health and nutrition examination survey. J Dermatol. 2015;42(2):148–153.
97. W.Li, J.Han, H.K.Choi, et al. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175(5):402–413.
98. L.Zou, S.B.Lonne-Rahm, A.Helander, et al. Alcohol intake measured by phosphatidylethanol in blood and the lifetime drinking history interview are correlated with the extent of psoriasis. Dermatology. 2015;230(4):375–380.
99. S.Gerdes, B.Dethlefs, Y.Personke, et al. Online weight-loss coaching for patients with psoriasis: results of a pilot study. Br J Dermatol. 2016;174(3):674–676.
100. WHO. Global Report on Psoriasis. 2016 [cited 2016 Mar29]. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf•• Comprehensive report from the World Health Organization on psoriasis, including burden of disease and impact of management.
101. Sundhedsstyrelsen. National Klinisk Retningslinje for Psoriasis. 2016 [cited 2016 Mar29]. Available from: https://sundhedsstyrelsen.dk/da/udgivelser/2016/~/media/8A7C8C59AD5249C2B433530466C1EDB6.ashx
102. A.B.Kimball, D.Gladman, J.M.Gelfand, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–1042.
103. I.L.Tablazon, A.Al-Dabagh, S.A.Davis, et al. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol. 2013;14(1):1–7.
104. DDS. Anbefalinger for vurdering af risiko for kardiovaskulær sygdom hos patienter med psoriasis og psoriasis artrit. 2016 [cited 2016 Mar16]. Available from: http://www.dds.nu/wp-content/uploads/2012/08/Anbefalinger-for-vurdering-af-risikoen-for-kardiovaskulær-sygdom.pdf
105. C.Banerjee, Y.P.Moon, M.C.Paik, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan study. Stroke. 2012;43(5):1212–1217.
106. H.Masuda, T.Miyazaki, K.Shimada, et al. Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol. 2014;64(5):366–370.
107. S.D.Fenerty, C.West, S.A.Davis, et al. The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence. 2012;6:127–135.
108. P.M.Ridker. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc. 2013;124:174–190.